

## 6 Literaturverzeichnis

Aarnoudse CA, van den Doel PB, Heemskerk B und Schrier PI: Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1, *Int J Cancer*. 1999;82(3):442-448

Albert ML, Sauter B und Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class-I-restricted CTLs, *Nature*. 1998;392(5): 86-89

Anichini A, Mortarini R, Macalli C, Sqarcina P, Fleischhauer K, Mascheroni L und Parmiani G: Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma, *J Immunol*. 1996;156:208-217

Anichini A, Molla A, Mortarini R, Tragni G, Bersani I, Di Nicola M, Gianni AM, Pilotti S, Dunbar R, Cerundolo V und Parmiani G: An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from Immune surveillance in metastatic lesions, *J Exp Med*. 1999;190(5):651-668

Arnold B, Schonrich G und Hammerling GJ: Multiple ways of peripheral tolerance, *Immunol Today*. 1993;14(1):12-14

Asai T, Storkus WJ und Whiteside TL: Evaluation of the Modified ELISPOT Assay for gamma interferon production in cancer patients receiving antitumor vaccines, *Clin Diagn Lab Immunol*. 2000;7(2):145-154

Asemissen AM, Nagorsen D, Keilholz U, Letsch A, Schmittel A, Thiel E und Scheibenbogen C: Flow cytometry determination of intracellular or secreted IFN $\gamma$  for the quantification of antigen reactive T cells, *J Immunol Meth*. 2001;251(1-2):101-108

- Atkins MB, Robertson M, Gordon MS, Lotze MT, Du Bois J, Ritz J, Sandler A, Edington HD und Sherman ML: Phase I evaluation of intravenous recombinant human IL-12 in patients with advanced malignancies, Proceedings of ASCO. J Clin Oncol. 1996;15:Abstr. No.718
- Aulitzky W, Gastl G, Aulitzky WE, Herold M, Kemmler J, Mull B, Frick J und Huber C: Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant Interferon- $\gamma$ , J Clin Oncol. 1989;12:1875-1884
- Baurain JF, Colau D, van Baeren N, Landry C, Martelange V, Vikkula M, Boon T und Coulie P, High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene, J Immunol. 2000;164:6057-6066
- Berthou C, Zang Y und Sasportes M: Granzyme B: an essential protease for the inflammatory response, Pathol Biol (Paris). 1998;46(8):617-624
- Bona CA, Casares S und Brumeanu TD: Towards development of T-cell vaccines, Immunol Today. 1998;19:126-133
- Boon T: Toward a genetic analysis of tumor rejection antigens, Adv Cancer Res. 1992(a):58:177-210
- Boon T, De Plaen E, Lurquin C, Van den Eynde B, van der Bruggen P, Traversari C, Amar-costesec A und Van Pel A: Identification of tumour rejection antigens recognized by T lymphocytes, Cancer Surv. 1992(b):13:2
- Boon T, Gajewski TF und Coulie PG: From defined human antigens to effective immunization?, Immunol. Today. 1995;16(7):334-336
- Boon T und van den Brueggen P: Human tumor antigens recognized by T cells, J Exp Med. 1996;183:725-729
- Boon T, Coulie PG und Van den Eynde B: Tumor antigens recognized by T cells, Immunol Today. 1997;18(6):267-268

- Brosterhus H, Brings S, Leyendeckers H, Manz RA, Miltenyi S, Radbruch A, Assenmacher M und Achmitz J: Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion, *Eur J Immunol*. 1999;29 4053
- Brooks AG, Boyington JC, Sun PD: Natural killer cell recognition of HLA-class I molecule, *Rev Immunogenet*. 2000;2(3):433-448
- Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N und Parmiani G: T-cell-recognition of melanoma –associated antigens, *J Cell Physiol*. 2000;182(3):323-331
- Chaux P, Martin MS und Martin F: T-cell co-stimulation by the CD28 ligand B7 is involved in the immune response leading to rejection of a spontaneously regressive tumor, *Int J Cancer*. 1996;66(2):244-248
- Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGovan P und Linsley PS: Costimulation of antitumor immunity by the AB7 counterreceptor for the T lymphocyte molecules CD28, and CTLA-4, *Cell*. 1992;71:1093-1102
- Chen L, Linsley PS und Hellstrom KE: Costimulation of T cells for tumor immunity, *Immunol Today*. 1993;14(10):483-486
- Chen YT, Stockert E, Tsang S, Coplan KA and Old L: Immunphenotyping of melanomas for tyrosinase: implications for vaccine development, *Immunology*. 1995;92:8125-8129
- Clay TM, Hobeika AC, Mosca PJ, Lysterly KH und Morse MA: Assays for Monitoring Cellular Immune Responses to Active Immunotherapy of Cancer, *Clin Cancer Res*. 2001;7:1127-1135
- Cormier JN, Panelli MC, Hackett JA, Bettinotti MP, Mixon A, Wunderlich A, Parker LL, Restifo NP, Ferrone S und Marincola FM: Natural variation of the expression of HLA and endogenous antigens modulates CTL recognition in an „in vitro“ melanoma model, *Int J Cancer*. 1999;80(5):781-790

Costelli RT, Gastaut JA und Olive D: Mechanism of tumor escape from immunologic response, *Rev Med Interne*. 1999(a):20(7):579-588

Costelli RT, Gastaut JA und Olive D: Tumor escape from immune surveillance, *Arch Immunol Ther Exp (Warsz)*. 1999(b):42(2):83-88

Coulie PG und Van Pel A: Defined Antigens recognized by T cells, *Curr Opin Oncol*. 1993: 5(6):1043-1048

Coulie PG: Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines, *Mol Med Today*. 1997:6:261-269

Coulie PG, Ikeda H, Baurain JF und Chiari R: Antitumor immunity at work in a melanoma patient, *Adv Cancer Res*. 1999:76:213-242

Currie GA: Eighty years of immunotherapy: A review of immunological methods used for the treatment of human cancer, *Br J Cancer*. 1972:26:141-151

Czerkinsky C, Anderson G, Ekre HP, Nilsson LA, Klareskog L und Ouchterlony O: Reverse ELISPOT assay for clonal analysis of cytokine production I. Enumeration of  $\gamma$ -interferon-secreting cells. *J Immunol Methods*. 1988:110:29-36

Del Vecchio M und Parmiani G: Cancer vaccination, *Forum (Genova)*. 1999:9(3):239-256

Denfeld RW, Dietrich A, Wuttig C, Tanczos E, Weiss JM, Vanscheidt W, Schöpf E und Simon JC: In situ expression of B7 and CD28 receptor families in human malignant melanoma : relevance for T-cell-mediated anti-tumor immunity, *Int J Cancer*. 1995:62:259-265

Di Fabio S, Mbawuike IN, Kiyono H, Fujihashi K, Couch RB, McGhee JR: Quantification of human influenza virus-specific cytotoxic T lymphocytes: correlation of cytotoxicity and increased number of IFN  $\gamma$  producing CD8<sup>+</sup> T cells, *Int Immunol*. 1993:6:11-19.

- Dobrzanski MJ, Reome JB und Dutton RW: Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor, *J Immunol.* 2000;164(2):916-925
- Drexler I, Antunes E, Schmitz M, Wölfel T, Huber C, Erfle V, Rieber P, Theobald M und Sutter G: Modified Vaccinia virus Ankara for delivery of human Tyrosinase as Melanoma-associated antigen: Induction of Tyrosinase- and Melanoma-specific HLA-A\*0201-restricted cytotoxic T cells „in vitro“ and in vivo, *Cancer Res.* 1999;59:4955-4963
- D'Souza S, Rimoldi D, Lienard D, Lejeune F, Cerottini JC and Romero P: Circulating Melan A/MART-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype, *Int J Cancer.* 1998;78:699-706
- Dunnion DJ, Cywinski AL, Tucker VC, Murray AK, Rickinson AB, Coulie P und Browning MJ: Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells „in vitro“, *Immunology.* 1999;98(4):541-550
- Dutton RW, Bradley LM und Swain SL: T cell memory, *Annu Rev Immunol.* 1998;16:201-223
- Fagerberg J, Steinitz W, Wigzell H, Akzelof P und Mellstedt H: Human anti-idiotypic antibodies induced a humoral cellular immune response against a colorectal carcinoma-associated antigen in patients, *Proc Natl Acad Sci.* 1995;92(11):4773-4777
- Farber DL: Cutting edge commentary: differential TCR signaling and the generation of memory T cells, *J Immunol.* 1998;160:535-539
- Farrar JD, Katz KH, Windsor J, Trush G, Scheuermann RH, Uhr JW und Street NE: Cancer Dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor dormant state, *J Immunol.* 1999;162(5):2842-2849

- Faure F, Even J, and Kourisly P: Tumor-specific immune response: current *in vitro* analyses may not reflect the *in vivo* immune status, *Crit Rev Immunol*. 1998;18(1-2):77-86
- Ferrone S und Marincola FM: Loss of HLA-class I antigens by melanoma cells: molecular mechanism, functional significance and clinical relevance, *Immunol Today*. 1995;16(10):487-495
- Fischer A und Malissen B: Natural and engineered disorders of lymphocyte development, *Science*. 1998;280(5361):237-243
- Finke J, Ferrone S, Frey A, Mufson A und Ochoa A: Where have all the T cells gone? Mechanism of immune evasion by tumors, *Immunol Today*. 1999;20(4):158-160
- Gamadia LE, Rentenaar RJ, Baars PA; Remmerswaal EBM, Surachno S, Weel JFL, Toebes M, Schumacher TNM, ten Berge IJM und van den Lier RAW: Differentiation of cytomegalovirus-specific CD8+T cells in healthy and immunosuppressed virus carriers, *Blood*. 2001;98:754-761
- Garrido F, Riuz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M und Stern PL: Implications for immunosurveillance of altered HLA-class I phenotypes in human tumours, *Immunol Today*. 1997;18(2):89-95
- Gattoni-Celli S und Cole DJ: Melanoma-associated tumor antigens and their clinical relevance to immunotherapy, *Semin Oncol*. 1996;23(6):754-758
- Germain RN: MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation, *Cell*. 1994;76:287-299
- Gilboa E: The makings of tumor rejection antigen, *Immunity*. 1999;11(3):263-270
- Graubert TA and Ley TJ: How do lymphocytes kill tumor cells?, *Clin. Cancer Res*. 1996;2:785-789

- Guéguen M, Patard JJ, Gaugler B, Brasseur F, Renauld JC, Van Canghai PJ, Boon T und Van den Eynde B: An antigen recognized by autologous CTLs on a human bladder carcinoma, *J Immunol*.1998;160:6188-6194
- Hahn S, Gehri R und Erb P: Mechanism and biological significance of CD4-mediated cytotoxicity, *Immunol Rev*.1995;146:57-79
- Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini JC und Tschopp J: Melanoma cell expression of Fas(Apo-1/CD95)Ligand: Implications for tumor escape, *Science*. 1996;274:1363-1366
- Hamann D, Baaars P, Rep M, Hooibrink B, Kerkhof-Garde S, Klein M und Van Lier R: Phenotypical and functional separation of memory and effector human CD8+ T cells, *J Exp Med*. 1997;186:1407-1418
- Hamann D, Roos MTL und van Lier R: Faces and phases of human CD8+ T-cell development, *Immunol Today*. 1999;20(4):177-180
- Herr W, Wölfel T, Heike M, Meyer zum Büschenfelde KH und Knuth A: Frequency analysis of tumor-reactive T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells, *Cancer Immunol Immunother*. 1994;39:93-99
- Herr W, Schneider J, Lohse AW, Meyer zum Bueschenfelde KH: Detection and quantification of blood-derived CD8+T lymphocytes secreting TNF $\alpha$  in response to HLA-A2.1-binding melanoma and viral peptide antigens, *J Immunol Methods*. 1996;191:131-143
- Hom S, Topalian SL, Simonis T, Mancini M und Rosenberg SA: Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocytes antigen restriction, *J Immunother*. 1991;10:153-164

- Hom S, Schwarzentrubber D, Rosenberg S und Topalian S: Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared antigens, *J Immunother.* 1993;13:18-30
- Hu J, Kindsvogel W, Busby S, Bailey MC, Shi YY und Greenberg PD: An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissue, *J Exp Med.* 1993;177:1681-1690
- Imro MA, Manici S, Russo V, Cosogno G, Bellone M, Rugarli C, Traversari C and Protti MP: Major histocompatibility class I restricted cytotoxic T cells specific for natural melanoma peptides recognize unidentified shared melanoma antigen(s), *Cancer Res.* 1999;59:2287-2291
- Itoh K, Tilden AB und Balch C: Interleukin-2 activation of cytotoxic T lymphocytes infiltrating into human metastatic melanoma, *Cancer Res.* 1986;46:3011-3017
- Jäger D, Jäger E und Knuth A: Vaccination for malignant melanoma: recent development, *Oncology.* 2001;60(1):1-7
- Jäger E, Ringhoff E, Karbach J, Arand M, Oesch F und Knuth A: Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8<sup>+</sup> cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo, *Int J Cancer.* 1994;58:330-339
- Jäger E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar R, Lee SY, Jangbluth A, Jäger D, Arand M, Ritter G, Cerundolo V, Dupont B, Chen YT, Old LJ und Knuth A: Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses, *Proc Natl Acad Sci.* 2000 (a):97(9):4760-4756
- Jäger E, Gnjatic S, Nagata Y, Stockert E, Jäger D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffmann E, Arand M, Old LJ und Knuth A: Induction of primary NY-



ESO-1 immunity: CD8<sup>+</sup> T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers, *Proc Natl Acad Sci.* 2000(b):97(22):12198-12203

Karanikas V, Colou D, Baurain JF, Chiari R, Thonnard J, Gutierrez-Roelens I, Goffinet C, Van Schaftigen EV, Weynants P, Boon T und Coulie PG, High frequencies of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable in HLA-tetramers in the blood of a lung carcinoma patient with long survival, *Cancer Res.* 2001:61(9):3718-3724

Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhus MR, Kang X, Sakaguchi K, Apella E und Rosenberg SA, Identification of new melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, -A3 alleles, *J Immunol.* 1998:161(12):6985-6992

Kawakami Y, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF, Wunderlich RF Yanelli JR und Rosenberg SA: Recognition of shared melanoma antigens in association with major HLA-alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma, *J Immunother.* 2000:23(1):17-27

Kedl RM, Mescher MF: Qualitative differences between naive and memory T cells make a major contribution to the more rapid and efficient memory CD8<sup>+</sup> T cell response, *J Immunol.* 1998:161(2):674-683

Keilholz U, Stoter G, Punt CJA, Scheibenbogen C, Lejeune F und Eggermont AMM, Recombinant IL-2-based treatments for advanced melanoma: The experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group, *Cancer J Sci Am.* 1997:3:22-28,

Keilholz U und Eggermont AM: The role of interleukin-2 in the management of stage IV melanoma, the EORTC melanoma cooperative group program, *Cancer J Sci Am.* 2000(a):6(1):99-103

Keilholz U, Scheibenbogen C, Hoffmann U, Servetopoulou F, Schmittel A, Siehl J, Foerster MH, Thiel E und Schadendorf D: Therapeutic versus adjuvant peptide vaccination: comparison of two phase I/II trials in melanoma patients, *J Clin Oncol, Proc ASCO 2000(b)*, Abstract # 101238

Kern F, Suresh IP, Brock C, Freistedt B, Radtke H, Schefold A, Blasczyk R, Reinke P, Schneider-Mergener J, Radbruch A, Walden P und Volk HD: T-cell epitope mapping by flow cytometry, *Nature Med.* 1998;4(8):975-978

Kiesling R, Kono K, Peterson M und Wassermann K: Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules, Springer *Sem Immunopathol.* 1996;18:227-242

Lalvani A, Brookes R, Hambleton S, Britton WJ, Hill A and MacMichael AJ: Rapid effector function in CD8<sup>+</sup> memory T cells, *J Exp Med.* 1997;186(6):859-865

Lanier LL: NK cell receptors, *Annu. Rev. Immunol.* 1998;16:359-393

Lanzavecchia A: Licence to kill, *Nature.* 1998(a):393:413-414

Lanzavecchia A: From antigen presentation to T cell activation, *Res Immunol.* 1998(b):149:629

Lanzavecchia A, Iezzi G und Viola A: From TCR engagement to T cell activation: a kinetic view of T cell behavior, *Cell.* 1999;96:1-4

Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA und Marincola FM: Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to „in vitro“ stimulation but does not lead to tumor regression, *J Immunol.* 1999(a):163(11):6292-6300

Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M und Davis MM: Characterization of circulating T cells specific for tumor associated antigens in melanoma patients, *Nature Med.* 1999(b):5(6):677-685

Legha S: Interferons in the treatment of malignant melanoma, *Cancer.* 1986:57:1675-1677

Levine AM: Lymphoma complicating immunodeficiency disorders, *Ann Oncol.* 1994:5:29-35

Levitsky HI, Lazenby A, Hayashi RJ und Pardoll DM: In vivo priming of two distinct antitumor effector populations. The role of MHC class I expression, *J Exp Med.* 1994:179:1215-1224

Lienard D, Ewalenko P, Delmotte JJ, Renard N und Lejeune FJ: High-dose recombinant necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma, *J Clin Oncol.* 1992:10:52-60

Lotze MT, Rubin JT, Carty S, Edington H, Ferson P, Landreneau R, Pippin B, Posner M, Rosenfelder D und Watson C: Gene therapy of cancer: a pilot study of IL-4-gene modified fibroblasts admixed with autologous tumor to elicit an immune response, *Hum Gene Ther.* 1994:5:41-55

Lucas S, De Plaen E, Boon T: MAGE-B5, MAGE-B6, MAGE-C2 and MAGE-C3 : Four new Members of the MAGE-Family with tumor-specific expression, *Int J Cancer.* 2000:87:55-60

Ludwig G, Jentzsch R und Nuri M: Spontanremissionen von Lungenmetastasen beim Hypernephrom: Fallbeschreibung und Literaturübersicht, *Med Klinik.* 1977:72:2118-2121

Mackensen A, Carcelain G, Viel S, Raynal MC, Michalaki H, Triebel F, Bosq J und Hercend T: Direct evidence to support the immunosurveillance concept in a human regressive melanoma, *J Clin Invest.* 1994:93(4):1397-1402

- Mackensen A, Herbst B, Chen JL, Köhler G, Noppen C, Herr W, Spagnoli GC, Cerundolo V und Lindemann A: Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vivo from CD34+ hematopoietic progenitor cells, *Int J Cancer*. 2000;86:385-392
- Maeurer M, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, Robbins P, Parmiani G, Storkus WJ und Lotze MJ: Tumor escape from immune recognition, *J Clin Invest*. 1996(a);98(7):1633-1641
- Maeurer M, Gollin SM, Storkus WJ, Swaney W, Karbach J, Martin D, Castelli C, Salter R, Knuth A und Lotze MJ: Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosom 6, *Clin Cancer Res*. 1996(b);2(4):641-652
- Mantovani A, Bottazzi B, Collotta F, Sozzani S, und Ruco L: The origin and function of tumor-associated macrophages, *Immunol Today*. 1992;13:265-270
- Marincola F: The multiple ways to tumor tolerance, *J Immunother*. 1997;20(3):178-179
- Mathé G, Amiel JL, Schwarzenberg L, Cattani A und Schneider M: Adoptive immunotherapy of acute leukemia, Experimental and clinical results, *Cancer Res*. 1965;25:1525-1531
- Matzinger P und Guerder S: Does T cell tolerance require a dedicated antigen-presenting cell?, *Nature*. 1989;338(6210):74-76
- Mazzochi A, Belli F, Manscheroni L, Vergetti C, Traversari C, Parmiani G und Anichini A: Frequency of T lymphocyte precursors (CTLp) interacting with autologous tumor via the T cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients, *Int J Cancer*. 1994;58:330-339
- Mazzochi A, Storkus WJ, Traversari C, Trasini P, Maeurer MJ, Rivoltini L, Vergetti C, Belli F, Anichini A, Parmiani G und Castelli C: Multiple melanoma-associated epitopes

- recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes, *J Immunol.* 1996;157(7):3030-3038
- McGee JM, Price JA, Mayes JS, Patten MR und Malnar KF: Melanoma vaccines as a therapeutic option, *Southern Medical Journal.* 1999;92:698-704
- Miyahira Y, Murata K, Rodriguez D, Rodriguez JR, Esteban M, Rodrigues MM, Zavala F: Quantification of antigen specific CD8+ Tcells using an ELISPOT assay, *J Immunol Methods.* 1995;181:45-54
- Mosmann TR, Li L und Sad S: Functions of CD8 T-cell subsets secreting different cytokine patterns, *Semin Immunol.* 1997;9(2):87-92
- Nagorsen D, Keilholz U, Rivoltini L, Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E, und Scheibenbogen C: Natural T cell response against EpCAM, her-2/neu and CEA in patients with advanced melanoma, *Cancer Res.* 2000;2:275-281
- Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G und Schadendorf D: Vaccination of melanoma patients with peptide- or tumor-lysate-pulsed dendritic cells, *Nat.Med.* 1998;4(3):28-333
- Nielsen MB und Marincola FM: Melanoma vaccines: the paradox of T cell activation without clinical response, *Cancer Chemother Pharmacol.* 2000(a):46:62-66
- Nielsen MB, Monsurro V, Migueles SA, Wang E, Perez-Diz A, Lee KH, Kammula U, Rosenberg SA und Marincola FM: Status of activation of circulating vaccine-elicited CD8+ T cells, *J Immunol.* 2000(b): 165:2287-2296
- Nishimura MI, Avichezer D, Custer MC, Lee CS, Chen C, Parkhurst MR, Diamont RA, Robbins PF, Schwartzentruber DJ und Rosenberg SA: MHC-claas I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte, *Cancer Res.* 1999;59(24):6230-6238

- Ohnmacht GA und Marincola FM: Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma, *J Cell Physiol.* 2000;182(3):332-338
- Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA and Restifo NP: Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes, *Proc Natl Acad Sci.* 1999;96(6):2982-2987
- Overwijk WW and Restifo NP: Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other", *Crit Rev Immunol.* 2000;20(6):433-450
- Overwijk WW and Restifo NP: Creating therapeutic cancer vaccines: notes from the battlefield, *Trends Immunol.* 2001;22(1):5-7
- Palermo B, Campanelli R, Matovani S, Lantelme E, Manganoni AM, Carella G, Da Prada G, Della Cuna GR, Romagne F, Gauthier L, Necker A and Giachino C: Diverse expansion potential and heterogeneous avidity in tumor-associated antigen-specific T lymphocytes from primary melanoma patients, *Eur J Immunol.* 2001;31 (2):412-20
- Parmiani G, Anichini A and Fossati G: Cellular immune response against autologous human malignant melanoma: are „in vitro“ studies providing a framework for a more effective immunotherapy?, *J Natl Cancer Inst.* 1990;82(5):361-70
- Pass HA, Schwartz SL, Wunderlich JR and Rosenberg SA: Immunization of patients with melanoma peptide vaccines: immunological assessment using the ELISPOT assay, *Cancer J Sci Am.* 1998;4(5):316-323
- Pawelec G, Zeuthen J and Kiessling R: Escape from host-antitumor immunity, *Crit Rev Oncog.* 1997;8(2-3):111-141

- Pham CT und Ley TJ: The role of granzyme B cluster proteases in cell-mediated cytotoxicity, *Semin Immunol.* 1997;9(2):127-133
- Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Lienard D, Lejeune F, Fleischhauer K, Cerundolo V, Cerottini JC und Romero P: High frequencies of naïve Melan-A/Mart-1 specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals, *J Exp Med.* 1999;190:705-715
- Redmann BG, Flaherty L, Chou T, Kraut M, Martino S, Simon D, Valdivieso M und Graoves E: Phase I trial of recombinant macrophage stimulating factor by rapid intravenous infusion in patients with cancer, *J Immunother.* 1992;12:50-54
- Restifo NP und Rosenberg MD: Development of recombinant and synthetic vaccines for the treatment of melanoma, *Curr Opin Oncol.* 1999;11:50-57
- Reynolds SR, Oratz R, Shapiro RL, Hao, P, Yun Z, Fotino M, Vukmanovic S und Bystryn JC: Stimulation of CD8+ T cell responses to MAGE-3 and MelanA/MART-1 by immunization to a polyvalent melanoma vaccine, *Int J Cancer.* 1997;72:972-976
- Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo NP, Topalian SL, Simonis TB und Rosenberg SA: Quantitative correlation between HLA class I expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes, *Cancer Res.* 1997;55(14):149-157
- Robbins P und Kawakami Y: Human tumor antigens recognized by T cells, *Curr Opin Immunol.* 1996;8:628-636
- Romero P, Cerottini JC und Waanders GA: Novel Methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy, *Mol Med Today.* 1998(a):7:305-312
- Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC und Cerundolo V: Ex vivo staining of metastatic lymph nodes by class I major

histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes, *J Exp Med.* 1998(b):188(9):1641-1650

Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH und White DE: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, *Nat Med.* 1998;4(3):321-327

Sarzotti M: Immunologic tolerance, *Curr Opin Hematol.* 1997;4(1):48-52

Scheibenbogen C, Lee KH, Mayer S, Stefanovic S, Moebius U, Rammensee HG und Keilholz U: A sensitive Elispot assay for detection of CD8+ lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients, *Clin Cancer Res.* 1997(a):3:221-226

Scheibenbogen C, Lee KH, Stefanovic S, Witzens M, Willhauck M, Waldmann V, Naehr H, Rammensee HG und Keilholz U: Analysis of the T cell response to tumor and viral peptide antigens by an IFN $\gamma$ -ELISPOT assay, *Int J Cancer.* 1997(b):71:932-936

Scheibenbogen C, Schmittel A, Keilholz U, Allgäuer T, Hoffmann U, Max R Thiel E und Schadendorf D: Phase II trial of vaccination with tyrosinase peptides and GM-CSF in melanoma, *J Immunotherapy.* 2000(a):23:275-281

Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel A, Cerrotini JC, Woelfel T, Eggermont AMM und Keilholz U: Quantification of antigen-reactive T cells in the peripheral blood by IFN $\gamma$ -ELISPOT assay and chromium-release assay: a four-centre comparative trial, *J Immunol Methods.* 2000(b):244(1-2):81-9.

Schmittel A, Keilholz U und Scheibenbogen C: Evaluation of the interferon- $\gamma$  ELISPOT assay for quantification of peptide specific T lymphocytes from peripheral blood, *J Immunol Methods.* 1997;210:167-174



- Schmittel A, Keilholz U, Max R, Thiel E und Scheibenbogen C: Induction of tyrosinase-specific T cells by the treatment with DTIC, Cisplatin, IFN $\alpha$  +IL-2 in patients with metastatic melanoma, *Int J Cancer*. 1999;80:39-45
- Schmittel A, Keilholz U, Thiel E und Scheibenbogen C: Quantification of tumor-specific T lymphocytes with the ELISPOT assay, *J Immunother*. 2000;23(3):289-95
- Schmittel A, Keilholz U, Bauer S, Kuhne U, Stefanovic S, Thiel E und Scheibenbogen C: Application of the IFN-gamma ELISPOT assay to quantify T cell responses against proteins, *J Immunol Methods*. 2001;247(1-2):17-24.
- Sedlmayr R, Rabinowich H, Elder EM, Ernstoff MS, Kirkwood JM, Herberman RB und Whiteside TL: Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells, *J Immunother*. 1991;10:336-346
- Seliger B, Maeuer MJ und Ferrone S: Antigen-processing machinery breakdown and tumor growth, *Immunol today*. 2000;21(9):455- 464
- Shi L, Mai S, Isreals S, Brown K, Trapani JA und Greenberg AH: Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization, *J Exp Med*. 1997;185(5):855-866
- Shresta S, Pham CT, Thoma DA, Graubert TA und Ley TJ: How do cytotoxic lymphocytes kill their targets ?, *Curr Opin Immunol*. 1998;10(5):581-587
- Slingluff CL, Graham D, Skipper J, Kittlesen D, Deacon D, Colella T, Harthun N, Huczko E, Darrow T, Innes D, Golden W und Engelhard V: Immunologic escape variant melanomas with normal MHC expression and antigen processing lack multiple melanocytic differentiation antigens, *J Immunother*. 1996;19:460

- Somasundaram R, Robbins P, Moonka D, Loh E, Marincola F, Patel A, Guerry D und Herlyn D: CD4(+), HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma cells, *Int J Cancer*. 2000;85(2):253-259
- Starzl TE, Porter KA, Iwatsuki S, Rosenthal JT, Shaw BW, Atchinson RW: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy, *Lancet*. 1990;1:583-587
- Sun Y, Moler P, Berking C, Schlupen EM, Volkenandt M und Schadendorf D: In vivo selective expansion of a tumor-specific cytotoxic T-cell clone derived from peripheral blood of a melanoma patient after vaccination with gene-modified autologous tumor cells, *Immunology*. 1999(a);98(4):535-540
- Sun Y, Paschen A und Schadendorf D: Cell-based vaccination against melanoma-background, preliminary results, and perspective, *J Mol Med*. 1999(b);77(8):593-608
- Suni MA; Picker LJ und Maino VC: Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry, *J Immunol Methods*. 1998;212:89
- Tan LC, Gudgeon N, Annels NE; Hansasuta P, O'Callaghan CA, Rowland-Jones S, McMichael AJ, Rickinson AB und Callan MFC: A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers, *J Immunol*. 1999;162:1827-1835
- Thomas WD und Hersey P: TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells., *J Immunol*. 1998;161(5):2195-200.
- Topalian SL, Solomon D und Rosenberg SA: Tumor-specific cytolysis by lymphocytes infiltrating human melanomas, *J Immunol*. 1989;142(10):3714-25
- Vales-Gomez M, Reyburn H und Strominger J: Interaction between the human NK receptors and their ligands, *Crit Rev Immunol*. 2000;20(3):223-244

Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC und Romero P: Naturally occurring human lymphocyte antigen restricted CD8+ cell response to the cancer testis antigen NY-ESO-1 in melanoma patients, *Cancer Res.* 2000(a):60(16):4499-4506

Valmori D, Dutoit V, Lienard D, Lejeune F, Speiser D, Rimoldi D, Cerundolo V, Dietrich P, Cerottini JC und Romero P: Tetramer-guided analysis of TCR-beta-chain usage reveals a large repertoire of melan-A specific CD8+T cells in melanoma patients, *J Immunol.* 2000(b):165:533-538

Van den Eynde BJ und Van den Brüggen P: T cells defined tumor antigens, *Curr Opin Immunol.* 1997:9(5):684-693

Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG Jr und Pinedo HM: Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial, *Lancet.* 1999:353(9150):345-50

Wang RF: Human tumor antigens: implications for cancer vaccine development, *J Mol Med.* 1999:77(9):640-655

Whittington R and Faulds D: Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer, *Drug.* 1993:46:446-514

Williams N: Tumor cells fight back to beat immune system, *Science.* 1996:274:1302

Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde KH und Boon T: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes, *Eur J Immunol.* 1994:24:759-764

Yannelli JR, Hyatt C, McConnell S, Hines K, Jacknin L, Parker L, Sanders M und Rosenberg SA: Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience, *Int J Cancer*. 1996;65(4):413-21

Yee C, Savage PA, Lee PP, Davis MM und Greenberg PD: Isolation of high avidity melanoma-reactive CTL from heterogenous populations using peptide-MHC tetramers, *J Immunol*. 1999;162:2227-2234

Yee C, Riddell SR und Greenberg PD: In vivo tracking of tumor-specific T cells, *Cur Opin Immunol*. 2001;13:141-146

Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O'Shea JJ, Powers GC, Urba WJ und Ochoa AC: Alterations in T cell receptor and signal transduction molecules in melanoma patients, *Clin Cancer Res*. 1995;11(1):1327-1335